- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
August 28th, 2010
Lynn Kirkpatrick, CEO and president of Ensysce Biosciences, says her company has developed a way to use nanotubes so they can enter cancer cells and prevent tumors from growing.
• Elevator pitch: Using tiny particles called carbon nanotubes to deliver treatments to individual cancer cells.
• The idea: Drugs delivered through the bloodstream have a hard time entering cells. But nanotubes, which are 1 to 2 nanometers in diameter and can carry large therapy molecules, pass easily out of the bloodstream and directly through cell membranes into cancer cells. Ensysce Biosciences says it has developed a way to attach a cancer therapy, known as short interfering RNA, to nanotubes so they can enter cancer cells and prevent the tumors from growing.
• Users: None. The company plans to start studies required by the FDA during the next six to 12 months so it can then gain approval to start clinical trials.
• The brains: Bob Gower founded the company in 2008 as spinoff of Carbon Nanotechnologies, set up to commercialize discoveries by a co-owner, the late Richard Smalley, in nanotechnology. Ensysce CEO Lynn Kirkpatrick co-founded and served as head of ProlX Pharmaceuticals before it was acquired in 2006.
|Related News Press|
News and information
Successful boron-doping of graphene nanoribbon August 27th, 2015
Molecular trick alters rules of attraction for non-magnetic metals August 5th, 2015
Global Carbon Nanotubes Industry 2015: Acute Market Reports August 4th, 2015
Developing Component Scale Composites Using Nanocarbons August 26th, 2015
Engineering a better 'Do: Purdue researchers are learning how August 4th, 2015
Glitter from silver lights up Alzheimer's dark secrets August 25th, 2015
Cervical cancer detection goes portable August 25th, 2015
How UEA research could help build computers from DNA August 19th, 2015
Biophysics: Formation of swarms in nanosystems August 18th, 2015